Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 725 of 1463 entries
View as:

Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05016544 Org: User:
Start: 07/28/21 End: 02/01/25 Due: 02/01/26

Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00652587 Org: User:
Start: 01/31/02 End: 12/31/07 Due: 12/31/08

A Controlled Study of Uric Acid on the Progression of IgA Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT00793585 Org: User:
Start: 07/31/07 End: 06/30/09 Due: 06/30/10

Comparison of Different Subsequent Treatments After Radical Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00806117 Org: User:
Start: 02/25/08 End: 12/31/20 Due: 12/31/21

Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01211210 Org: User:
Start: 06/30/10 End: 06/30/20 Due: 06/30/21

Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

Phase: N/A Priority: Normal
NCT ID: NCT06742502 Org: User:
Start: 11/12/24 End: 12/30/29 Due: 12/30/30

The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00720668 Org: User:
Start: 06/30/06 End: 05/31/10 Due: 05/31/11

Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04547829 Org: User:
Start: 10/10/20 End: 05/10/23 Due: 05/10/24

CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04715321 Org: User:
Start: 02/15/13 End: 12/31/21 Due: 12/31/22

Reconstruction Technology to Auxiliary Diagnosis and Guarantee Patient Privacy

Phase: N/A Priority: Normal
NCT ID: NCT05058599 Org: User:
Start: 05/10/20 End: 01/30/22 Due: 01/30/23

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06904300 Org: User:
Start: 08/15/25 End: 12/31/28 Due: 12/31/29

Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06529549 Org: User:
Start: 07/24/24 End: 12/31/27 Due: 12/31/28

The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients

Phase: N/A Priority: Normal
NCT ID: NCT02505139 Org: User:
Start: 12/31/14 End: 08/31/16 Due: 08/31/17

The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Phase: N/A Priority: Normal
NCT ID: NCT03192644 Org: User:
Start: 07/01/17 End: 12/31/24 Due: 12/31/25

Early Changes Between Lenticule Extraction and Small-Incision Lenticule Extraction

Phase: N/A Priority: Normal
NCT ID: NCT02540785 Org: User:
Start: 04/30/14 End: 12/31/14 Due: 12/31/15

Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis

Phase: N/A Priority: Normal
NCT ID: NCT04588818 Org: User:
Start: 02/01/20 End: 12/31/23 Due: 12/31/24

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT04022005 Org: User:
Start: 06/19/19 End: 03/11/23 Due: 03/11/24

Comparison of Intravenous Anesthetics to Volatile Anesthetics on Postoperative Cognitive Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT01809041 Org: User:
Start: 03/31/13 End: 04/30/19 Due: 04/30/20

Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03045484 Org: User:
Start: 05/31/16 End: 06/30/18 Due: 06/30/19

Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy

Phase: N/A Priority: Normal
NCT ID: NCT02203682 Org: User:
Start: 07/31/14 End: 07/31/22 Due: 07/31/23

Modified MRCUKALLâ…«/ECOGE2993 Regimen for ALL

Phase: N/A Priority: Normal
NCT ID: NCT02660762 Org: User:
Start: 01/31/16 End: 01/31/19 Due: 01/31/20

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04548271 Org: User:
Start: 09/30/20 End: 10/31/23 Due: 10/31/24

Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03020329 Org: User:
Start: 11/14/16 End: 12/30/22 Due: 12/30/23

Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03668730 Org: User:
Start: 10/19/18 End: 12/30/23 Due: 12/30/24

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Phase: N/A Priority: Normal
NCT ID: NCT05115409 Org: User:
Start: 06/01/22 End: 12/31/24 Due: 12/31/25